"Our recently launched e-commerce site for Marley Drug has huge potential and will be our most significant driver of growth and major source of our profits moving forward."
"Our fixed-price, fastest DNA-to-IND program is packaged in a standardized platform to allow clients to bring a new antibody molecule to IND filing in a rapid amount of time."
"The focus of our integrated Translational Pharmaceutics programs is to provide the customer with a development platform capable of responding in real-time to emerging development data and maintain an overall timeline to proof of concept."
"We were excited to secure equity investment from Signet Healthcare Partners and have since almost doubled in size in both our capacity and talent pool."
"Insmed developed a drug-device combination that became the first approved therapy to treat patients with a refractory form of a rare and serious lung infection."
SENIOR VICE PRESIDENT OF POLICY, RESEARCH AND MEMBERSHIP, PHRMA
"Our organization advocates for public policies that encourage the research and development and manufacturing of new medicines that allow patients to lead longer, healthier, and more productive lives."
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.